The binding of RelA with BDR4 blocks its ubiquitination and inhibits its subsequent proteasome-mediated degradation, leading to the excessive activation of NF-κB and aberrant proliferation of cancer cells (Wu et al., 2013; Zou et al., 2014). Here, NFKB1 is linked to cancer.